drugset
drugset / Trial / NCT01309945

Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

NCT01309945 ↗

Phase 2 Completed 889 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued duloxetine in the treatment of patients with treatment resistant depression (TRD).

Timeline

Start
2011-04
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Duloxetine Small molecule 30 mg Oral
Comparator Duloxetine Small molecule 60 mg Oral
Subject Liafensine Small molecule 0.5 mg Oral
Subject Liafensine Small molecule 2 mg Oral

Indications

depressive disorder